The Psychedelic Drug Revolution has begun. Standing in the way are politicians and regulators, saddled with archaic anti-drug phobias. They need to be educated.
Psychedelics
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics
Mydecine reports a net loss of CAD$5.2 million for Q1 2021, with cash and cash equivalents of CAD$11.3 million at the end of the quarter.
FDA Endorses Psychedelics 'Guided Experience' Model
The FDA has approved the use of MDMA by therapists -- to better prepare them to administer MDMA-assisted psychotherapy.
Decriminalizing Psychedelic Drugs in California: As State Senate Considers Bill, Debate Continues
A bill to decriminalize psychedelic drugs is currently being considered by the California Legislature.
Psychedelic Drugs To The Rescue: Professional Sports Turn To Psychedelics
Traumatic Brain Injury is another major treatment market targeted by psychedelics R&D. TBIs are now a health crisis in many professional sports. Opportunity knocks.
Turn On, Tune In, Feel Better: The Rise of Psychedelic Therapy in Texas
On the day it opened in early May, Field Trip Health’s therapeutic facility in Houston’s uptown neighborhood looked a little like a high-end strip-mall spa. Dressed in a floral shirt, Matt Emmer, the company’s director of operations and business development, showed me the clinic’s amenities.
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
MindMed reports a net loss of CAD$14 million for Q1, with US$160 million in cash and a total cash burn for the quarter of CAD$10 million.
Media Coverage Of Psychedelic Drugs Soars
For a solid month, there has been an explosion in coverage of the psychedelic drug industry by the mainstream media.
The World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts to Research the Impact of Psychedelics on Traumatic Brain Injury
Wesana inks a multi-year research agreement with the World Boxing Council on psychedelics therapy for Traumatic Brain Injury (TBI).
Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation
Numinus fills several key roles including a new Director of Mergers and Acquisitions and a new Chief Communications Officer.
Some people with color blindness report improved color vision after psychedelic drug use
A new report published in Drug Science, Policy and Law suggests that psychedelic drugs may improve symptoms of color blindness.
World Boxing Council, Wesana Health Partnering To Examine Psychedelics As Potential Treatment For Traumatic Brain Injury
Since retiring from the National Hockey League in 2015 at age 30, Daniel Carcillo has dedicated his life to helping athletes and other people like himself who have suffered from traumatic brain injury.
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
Compass Pathways highlights for Q1 include two new patents and reports its Phase IIb clinical trial is on track.
Are Millennials Missing An Opportunity With Psychedelic Stocks?
Psychedelic drug stocks are a very progressive investing option for investors seeking high-growth opportunities. So why aren't more Millennials jumping on the bandwagon?
Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
Optimi Health and Numinus Wellness announce a new milestone in their partnership to develop an all-natural psilocybin extract.